Supplementary Material:

Treat-to-Target Outcomes with Tapinarof Cream in Three Phase 3 Trials for Plaque Psoriasis

April W. Armstrong, MD, Robert Bissonnette, MD, Raj Chovatiya, MD, PhD, Tina Bhutani, MD, Philip M. Brown, MD, JD, Anna M. Tallman, PharmD, Kim A. Papp, MD, PhD

Affiliations:

Dr. Armstrong is from the Division of Dermatology, University of California Los Angeles, Los Angeles, CA, USA

Dr. Bissonnette is from Innovaderm Research Inc., Montreal, QC, Canada

Dr. Chovatiya is from Rosalind Franklin University Chicago Medical School, North Chicago, IL, USA, and the Center for Medical Dermatology and Immunology Research, Chicago, IL, USA

Dr. Bhutani is from the University of California, San Francisco, CA, USA

Drs. Brown and Tallman are from Dermavant Sciences, Inc., Morrisville, NC, USA

Dr. Papp is from Probity Medical Research Inc. and Alliance Clinical Trials, Waterloo, ON, Canada, and the University of Toronto, Toronto, ON, Canada

Author for Correspondence:

April W. Armstrong, MD, MPH

aprilarmstrong@post.harvard.edu

Supplementary Figure S1. Design of the PSOARING Trial Program: Three Phase 3 Trials of Tapinarof Cream 1% Once Daily for Mild to Severe Plaque Psoriasis (PSOARING 1, 2, and 3)



Includes patients receiving continuous or intermittent treatment with tapinarof monotherapy, due to vehicle treatment in the 12-week pivotal trials (PSOARING 1 and PSOARING 2) and the forced-withdrawal design of PSOARING 3 (treatment was stopped when patients achieved PGA=0).

*Patients with PGA=2 (mild) and PGA=4 (severe) limited to ~10% each of the total randomized population; approximately 80% of the total randomized population had baseline PGA=3 (moderate).

†Patients electing not to participate in the long-term extension trial had a follow-up visit 4 weeks after completion of the treatment period.

BSA, body surface area; PGA, Physician Global Assessment; R, randomized; QD, once daily.

Supplementary Figure S2. Kaplan–Meier Estimates of Time to Percent BSA Affected Targets of (a) ≤1%, and (b) ≤0.5% Achieved by Patients with Mild to Severe Plaque Psoriasis Treated with Tapinarof Cream 1% QD (PSOARING 1, 2, and 3)



Includes patients receiving continuous or intermittent treatment with tapinarof monotherapy, due to vehicle treatment in the 12-week pivotal trials (PSOARING 1 and PSOARING 2) and the forced-withdrawal design of PSOARING 3 (treatment was stopped when patients achieved PGA=0).

95% Hall–Wellner confidence bands are displayed (dotted lines).

Pooled analysis (observed cases).

BSA, body surface area; PGA, Physician Global Assessment; QD, once daily.

Supplementary Figure S3. Kaplan–Meier Estimates of Time to Total PASI Score Targets Achieved by Patients with Mild to Severe Plaque Psoriasis Treated with Tapinarof Cream 1% QD (PSOARING 1, 2, and 3)



Includes patients receiving continuous or intermittent treatment with tapinarof monotherapy, due to vehicle treatment in the 12-week pivotal trials (PSOARING 1 and PSOARING 2) and the forced-withdrawal design of PSOARING 3 (treatment was stopped when patients achieved PGA=0).

95% Hall–Wellner confidence bands are displayed (dotted lines).

Pooled analysis (observed cases).

PASI, Psoriasis Area and Severity Index; PGA, Physician Global Assessment; QD, once daily.